The annual Alzheimer’s Association International Conference, the largest international meeting dedicated to advancing dementia science, will take place in London from 16th – 20th July. read more
A new study published in Nature reports the structure of tau using a magnified look at filaments in a patient with Alzheimer’s and explores what this might mean for the treatment of Alzheimer’s disease. read more
Publishing in Science Advances researchers present a computer-designed ‘antibody scanning’ strategy which generates a panel of antibodies that work on blocking amyloid buildup in a worm model.
Researchers publishing in PLOS Medicine have developed a polygenic hazard score (PHS) as a possible way of quantifying the likelihood of developing Alzheimer’s disease. read more
New research published in Scientific Reports investigates the underlying mechanism linking an association between diabetes and Alzheimer’s, suggesting excess glucose levels may be involved. read more
Publishing in Science Translational Medicine researchers claimed a drug targeting Tau – a protein that builds up in the brains of people with some neurodegenerative disorders, including Alzheimer’s – prevented loss of brain cells in experimental animals.
The association between Mediterranean-type diet and change in brain size across a 3-year period in older age (73-76 years) is assessed in new research publishing in the journal Neurology. read more
A study published in the Journal of Clinical Investigation claimed that a drug reduced memory loss and prolonged life in mice. read more
Publishing in JAMA Neurology, researchers reported an association between statin use and lower Alzheimer’s disease risk. They reported variation in lowering disease risk across race and ethnicity and type of statin. read more
Publishing in Nature, scientists reported that exposing mice to specific frequencies of LED light reduced the level of amyloid protein, a protein associated with Alzheimer’s disease, in the visual areas of the mouse brain. read more
Following the failure of the recent solanezumab trial the question now is where does Alzheimer’s research go from here? We have brought together four top experts to discuss:
Is the solanezumab trial a complete failure? Can we learn anything from it?
Is this the end for the amyloid hypothesis? Could we be going about this all wrong? Is Tau the answer?
What other drugs are in the pipeline? Do the solanezumab results lower our hopes for their success?
Are there other non-drug therapies on the horizon that might offer success?
Will we not progress until we get better at detecting and diagnosing this disease?
Do we think we will ever find a treatment? Is our only hope to reduce lifestyle risks as much as possible? read more
It has been announced that Solanezumab, an experimental Alzheimer’s treatment from Eli Lilly & Co, failed to slow the progression of the neurodegenerative disease. read more
A group of scientists have described their use of a specific gene therapy to treat Alzheimer’s disease in a mouse model. Publishing in the journal Proceedings of the National Academy of Sciences the scientists report that the upregulation of the PGC-1α gene brought about reduced biological markers of the disease and improved function in the mice. read more
A paper published in the journal PNAS has reported the identification of the mineral magnetite in human brains. The mineral has been implicated in negative health consequences and the authors suggest that the samples originate from air pollution. read more
An antibody therapy for the treatment of Alzheimer’s disease has been described in a paper published in the journal Nature in which the authors report its use in animals and a small number of patients where the treatment was able to reduce amyloid plaques which are thought to contribute to the disease. read more
In a new study, published in Nature Communications, researchers compared the actual number of dementia cases in the UK to earlier decades and previous predictions. They report a 20% drop in incidence of dementia between their two samples (1989-1994, 2008-2011) which they attribute mainly to a reduction in men. read more
Finding the causes of, and treatments for, Alzheimer’s disease is important to reduce the burden of ageing, and the authors of a paper published in the journal PNAS report the use as a therapy of a particular protein which is involved in inflammation. read more
A study published in the journal Nature has investigated mechanisms which control memory in mouse models of the disease. read more
An editorial published in the Journal of Alzheimer’s Disease has called for more research to investigate the role of microbes in the development of Alzheimer’s disease. read more
The aggregation of certain proteins is linked to the progression of Alzheimer’s disease and a group of scientist publishing in the journal Science Advances have reported their use of an anticancer drug to prevent this build up in a worm model organism. read more
